Predicate Ledger Insights U.S. FDA 510(k) & Recall Record (1976 to 2026)

Procurement & Medtech Counsel Guide · Empirical Regulatory Briefing

How Hospital Value Analysis Committees and Medtech Counsel Audit 510(k) Predicate History Before Procurement

Hospital Value Analysis Committees and medtech transaction counsel auditing vendor proposals can cross-verify 176,625 U.S. FDA 510(k) clearances across 15,610 manufacturers (40 consolidated M&A parent groups) and 4,799 product codes from accessdata.fda.gov, benchmarking vendor recall shares against the 7.43% national recalled-device baseline before executing supply contracts.

Updated: 2026-11-18 Publication ID: 45ee9f8facc7af9d031b Primary Sources: accessdata.fda.gov & open.fda.gov

Why Vendor RFP Self-Disclosures Miss Inherited Regulatory Exposure

When health-system Value Analysis Committees (VACs), supply-chain contracting officers, and medtech M&A counsel evaluate implantable prostheses, endovascular catheters, or ICU capital equipment, standard vendor Request for Proposal (RFP) questionnaires typically ask only for the primary FDA 510(k) K-number and any open field safety notices over the preceding 24 months. That narrow window routinely obscures three material operational considerations: legacy recalls filed under acquired subsidiary names, recurring platform-level design corrections across sibling K-numbers, and cohort-level recall density relative to clinical specialty peers.

Across Predicate Ledger's reconciled U.S. regulatory corpus (176,625 510(k) submissions, 27,147 implantable clearances, and 5,737 life-sustaining clearances), 46,481 clearances (26.32%) sit under consolidated corporate parent hierarchies uniting 1,087 historical applicant names. Meanwhile, geographic clearance density concentrates heavily in specialized regional engineering hubs led by California (27,214 clearances, 15.41% national share, 3,460 implantable clearances) and Massachusetts (9,295 clearances, 1,755 implantable clearances).

Table 1. Top U.S. State MedTech Clearance Hubs and Implantable Device Concentration (1976 to 2026)
State Hub Cleared 510(k) Devices National Share Implantable Clearances Distinct Manufacturers Median FDA Review Days
CA 27,214 15.41% 3,460 5,076 87.0
IL 25,686 14.54% 1,485 4,633 39.0
MA 9,295 5.26% 1,755 1,543 86.0
NJ 7,761 4.39% 2,010 1,094 85.0
FL 6,859 3.88% 1,823 1,762 90.0
NY 6,633 3.76% 271 1,534 82.0
MN 5,996 3.39% 1,113 857 84.5
PA 5,833 3.30% 1,604 884 89.0

Five-Step Quantitative 510(k) Procurement Due-Diligence Protocol

Clinical engineering directors, perioperative VAC chairs, and healthcare regulatory counsel can execute a reproducible pre-contract audit in under ten minutes using reconciled federal identifiers:

Step 1: Verify Exact K-Number, Three-Letter Product Code, and FOICLASS Risk Flags

Confirm the exact K-number on the vendor's FDA clearance letter and verify its assigned three-letter product code, regulation number, device class, implantable flag, and life-sustaining flag. In Orthopedic (OR), 92.0% of clearances (15,994 of 17,390) carry implantable designations requiring UDI lot traceability inside hospital EHR implant logs; in Gastroenterology and Urology (GU) and Anesthesiology (AN), 2,245 and 2,225 clearances carry life-sustaining designations requiring preventive-maintenance SLA covenants.

Step 2: Resolve Corporate Parent and Acquired Subsidiary Lineages

Audit the consolidated corporate parent alongside the named clearance applicant. Major medtech conglomerates unify dozens of acquired brands: Medtronic plc consolidates 139 legacy applicant strings (2,686 clearances, 552 cumulative Class I recall notices), Johnson and Johnson MedTech consolidates 113 names (2,725 clearances), Stryker consolidates 77 names (2,522 clearances), and Abbott Laboratories consolidates 76 names (1,587 clearances).

Step 3: Benchmark Cohort Recall Share Against Peer Product Codes (n >= 20)

Never evaluate a vendor's cumulative recall count in a vacuum. A 14% recalled-clearance ratio represents elevated exposure in Dental (DE, peer baseline 2.42%), yet sits near parity in percutaneous catheters (DQY, 13.84%) or intravascular administration sets (FPA, 14.03%) and well below facility ventilators (CBK, 22.18%). Always enforce a minimum denominator of 20 cleared submissions before interpreting percentage rates.

Step 4: Distinguish Open Recalls and Class I History From Routine Class II Software Updates

Separate currently open field notices from closed historical actions, and inspect the ratio of Class I to Class II events. Capital imaging vendors such as GE HealthCare (29.16% recalled 510(k) share; 1,386 Class II vs 143 Class I notices) and Siemens Healthineers (18.57% recalled share; 2,185 Class II vs 29 Class I notices) issue frequent Class II software and calibration updates managed via scheduled patches, whereas sterile-barrier or intravascular component recalls require lot-level inventory quarantine and replacement-credit clauses.

Step 5: Embed Post-Market Recall Covenants Into Master Supply Agreements

Legal counsel drafting Group Purchasing Organization (GPO) and health-system Master Supply Agreements should translate empirical 510(k) cohort exposure directly into clear commercial remedies. When procuring devices in cohorts whose recalled-clearance rate exceeds twice the 7.43% national benchmark, agreements should require direct electronic routing of all 21 CFR Part 806 Urgent Medical Device Corrections to clinical engineering, replacement or pro-rata capital credit for Class I quarantined stock, loaner equipment delivery SLAs for life-sustaining systems, and parent-company indemnification surviving subsidiary divestitures.

Table 2. Hospital VAC Pre-Procurement FDA 510(k) Audit Checklist and Contract Guardrails
Audit Dimension Primary Federal Record Quantitative Benchmark Recommended Contracting Guardrail
Clearance Authenticity CDRH PMN Archive (K-number) Exact applicant, decision date & 3-letter code match Require clearance letter & IFU intended-use match
Cohort Recall Baseline FOICLASS + Unified Recalls National recalled 510(k) share: 7.43% (n >= 20) Escalate VAC clinical review when vendor exceeds 2x peer cohort
Class I Recall History openFDA / CDRH Enforcement 3,677 Class I of 59,705 recalls (6.16%) Mandate replacement credit, loaner fleet & explant cost indemnity
Subsidiary M&A Lineage Consolidated Parent Rollup 46,481 clearances across 40 parent groups Bind parent guarantor to legacy subsidiary field-action SLAs
Implant / Life-Support Flag 21 CFR Product Classification 27,147 implant / 5,737 life-sustain 510(k)s Enforce UDI barcode integration & 24-hour field notice routing

Methodology and Procurement Audit Limitations

Procurement teams can run side-by-side vendor comparisons directly in the Peer Comparison Workbench and export CSV audit trails from the Device and Recall Explorer. Remember that larger manufacturers with multi-decade installed bases naturally accumulate higher cumulative 1976 to 2026 recall event counts, and proactive Class II software updates can reflect mature post-market quality systems rather than inferior hardware reliability. Always combine reconciled 510(k) lineage data with peer-reviewed clinical outcomes registries and FDA Establishment Inspection Report (EIR) findings.